New biotech Roxiant to tackle age-related diseases

Pharmacosmos heir Andreas Christensen, who recently founded the biotech company Roxiant, will use a protein found in people who live for an exceptionally long time to treat age-related diseases, and its first target is Huntington's disease.
Andreas Christensen has left his family's company Pharmacosmos to become CEO in the biotech business Roxiant. | Photo: Roxiant / PR
Andreas Christensen has left his family's company Pharmacosmos to become CEO in the biotech business Roxiant. | Photo: Roxiant / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN

Andreas Christensen flew the nest last year, leaving Pharmacosmos, which was founded by his paternal grandfather Henry Christensen and is still run by the family, to start biotech firm Roxiant.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading